mexiletine has been researched along with Allodynia in 14 studies
Mexiletine: Antiarrhythmic agent pharmacologically similar to LIDOCAINE. It may have some anticonvulsant properties.
mexiletine : An aromatic ether which is 2,6-dimethylphenyl ether of 2-aminopropan-1-ol.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the effects of IV lidocaine on spontaneous and evoked pain (allodynia and hyperalgesia) due to peripheral nerve injury (postherpetic neuralgia or nerve trauma) using quantitative sensory testing." | 9.11 | Systemic lidocaine in pain due to peripheral nerve injury and predictors of response. ( Attal, N; Bouhassira, D; Brasseur, L; Chauvin, M; Rouaud, J, 2004) |
| "The effect of the cyclooxygenase-2 (COX-2) inhibitor etodolac on the mechanical allodynia induced by paclitaxel was investigated in mice and compared with the effects of the nonselective COX inhibitors indomethacin and diclofenac, the selective COX-2 inhibitor celecoxib, the calcium channel α(2)δ subunit inhibitor pregabalin, the sodium channel blocker mexiletine, and the serotonin-norepinephrine reuptake inhibitor duloxetine." | 7.78 | Etodolac, a cyclooxygenase-2 inhibitor, attenuates paclitaxel-induced peripheral neuropathy in a mouse model of mechanical allodynia. ( Banno, K; Inoue, N; Ito, S; Kotera, T; Kyoi, T; Nakamura, A; Nogawa, M; Sasagawa, T; Tajima, K; Takahashi, Y; Ueda, M; Yamashita, Y, 2012) |
| "Static and dynamic allodynia occurred in a rat model of neuropathic pain induced by chronic constriction injury (CCI) of the sciatic nerve." | 5.35 | Effect of mexiletine on dynamic allodynia induced by chronic constriction injury of the sciatic nerve in rats. ( Kurebayashi, Y; Nakazato-Imasato, E; Tanimoto-Mori, S, 2009) |
| "Furthermore, fenvalerate-induced thermal allodynia and hyperalgesia were inhibited by the pretreatment with calphostin C." | 5.31 | Nociception and allodynia/hyperalgesia induced by intrathecal administration of fenvalerate. ( Kamei, J; Morita, K; Sasaki, M; Tanaka, S; Zushida, K, 2001) |
| "To investigate the effects of IV lidocaine on spontaneous and evoked pain (allodynia and hyperalgesia) due to peripheral nerve injury (postherpetic neuralgia or nerve trauma) using quantitative sensory testing." | 5.11 | Systemic lidocaine in pain due to peripheral nerve injury and predictors of response. ( Attal, N; Bouhassira, D; Brasseur, L; Chauvin, M; Rouaud, J, 2004) |
| "The effect of the cyclooxygenase-2 (COX-2) inhibitor etodolac on the mechanical allodynia induced by paclitaxel was investigated in mice and compared with the effects of the nonselective COX inhibitors indomethacin and diclofenac, the selective COX-2 inhibitor celecoxib, the calcium channel α(2)δ subunit inhibitor pregabalin, the sodium channel blocker mexiletine, and the serotonin-norepinephrine reuptake inhibitor duloxetine." | 3.78 | Etodolac, a cyclooxygenase-2 inhibitor, attenuates paclitaxel-induced peripheral neuropathy in a mouse model of mechanical allodynia. ( Banno, K; Inoue, N; Ito, S; Kotera, T; Kyoi, T; Nakamura, A; Nogawa, M; Sasagawa, T; Tajima, K; Takahashi, Y; Ueda, M; Yamashita, Y, 2012) |
| " In this study, we investigated the effects of M58373 on substance P release from sensory neurons in vitro and pain behaviors/responses in rats, compared with mexiletine." | 3.73 | Potent analgesic effects of a putative sodium channel blocker M58373 on formalin-induced and neuropathic pain in rats. ( Akada, Y; Amano, K; Fukudome, Y; Itoh, M; Ogawa, S; Yamamoto, I; Yamasaki, F, 2006) |
| "Drugs that are clinically effective (mexiletine and desipramine) or ineffective (fluoxetine) in the treatment of human neuropathic pain were evaluated for efficacy in rat models involving central sensitization (i." | 3.69 | The effects of mexiletine, desipramine and fluoxetine in rat models involving central sensitization. ( Hunter, JC; Jett, MF; McGuirk, J; Waligora, D, 1997) |
| "The development of hind paw mechanical allodynia was measured after BCAO using the von Frey test." | 1.43 | Effects of Adjuvant Analgesics on Cerebral Ischemia-Induced Mechanical Allodynia. ( Harada, S; Matsuura, W; Tokuyama, S, 2016) |
| "Static and dynamic allodynia occurred in a rat model of neuropathic pain induced by chronic constriction injury (CCI) of the sciatic nerve." | 1.35 | Effect of mexiletine on dynamic allodynia induced by chronic constriction injury of the sciatic nerve in rats. ( Kurebayashi, Y; Nakazato-Imasato, E; Tanimoto-Mori, S, 2009) |
| "Pretreatment with mexiletine, at doses of 3, 10 and 30 mg/kg, i." | 1.33 | Effect of mexiletine on vincristine-induced painful neuropathy in mice. ( Kamei, J; Nozaki, C; Saitoh, A, 2006) |
| "Furthermore, fenvalerate-induced thermal allodynia and hyperalgesia were inhibited by the pretreatment with calphostin C." | 1.31 | Nociception and allodynia/hyperalgesia induced by intrathecal administration of fenvalerate. ( Kamei, J; Morita, K; Sasaki, M; Tanaka, S; Zushida, K, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 9 (64.29) | 29.6817 |
| 2010's | 3 (21.43) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Shinozuka, T | 1 |
| Kobayashi, H | 1 |
| Suzuki, S | 1 |
| Tanaka, K | 1 |
| Karanjule, N | 1 |
| Hayashi, N | 1 |
| Tsuda, T | 1 |
| Tokumaru, E | 1 |
| Inoue, M | 1 |
| Ueda, K | 1 |
| Kimoto, H | 1 |
| Domon, Y | 1 |
| Takahashi, S | 1 |
| Kubota, K | 1 |
| Yokoyama, T | 1 |
| Shimizugawa, A | 1 |
| Koishi, R | 1 |
| Fujiwara, C | 1 |
| Asano, D | 1 |
| Sakakura, T | 1 |
| Takasuna, K | 1 |
| Abe, Y | 1 |
| Watanabe, T | 1 |
| Kitano, Y | 1 |
| Yamamoto, S | 1 |
| Kawashiri, T | 1 |
| Higuchi, H | 1 |
| Tsutsumi, K | 1 |
| Ushio, S | 1 |
| Kaname, T | 1 |
| Shirahama, M | 1 |
| Egashira, N | 1 |
| Matsuura, W | 1 |
| Harada, S | 1 |
| Tokuyama, S | 1 |
| Nakazato-Imasato, E | 1 |
| Tanimoto-Mori, S | 1 |
| Kurebayashi, Y | 1 |
| Ito, S | 1 |
| Tajima, K | 1 |
| Nogawa, M | 1 |
| Inoue, N | 1 |
| Kyoi, T | 1 |
| Takahashi, Y | 1 |
| Sasagawa, T | 1 |
| Nakamura, A | 1 |
| Kotera, T | 1 |
| Ueda, M | 1 |
| Yamashita, Y | 1 |
| Banno, K | 1 |
| Attal, N | 1 |
| Rouaud, J | 1 |
| Brasseur, L | 1 |
| Chauvin, M | 1 |
| Bouhassira, D | 1 |
| Kamei, J | 4 |
| Nozaki, C | 1 |
| Saitoh, A | 1 |
| Akada, Y | 1 |
| Ogawa, S | 1 |
| Amano, K | 1 |
| Fukudome, Y | 1 |
| Yamasaki, F | 1 |
| Itoh, M | 1 |
| Yamamoto, I | 1 |
| Jett, MF | 1 |
| McGuirk, J | 1 |
| Waligora, D | 1 |
| Hunter, JC | 1 |
| Zushida, K | 2 |
| Wu, WP | 1 |
| Nordmark, J | 1 |
| Wiesenfeld-Hallin, Z | 1 |
| Xu, XJ | 1 |
| Sasaki, M | 1 |
| Morita, K | 1 |
| Tanaka, S | 1 |
| Laird, JM | 1 |
| Carter, AJ | 1 |
| Grauert, M | 1 |
| Cervero, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Long Term Outcome After Serial Lidocaine Infusion in Peripheral Neuropathic Pain : A Pilot Study[NCT02217267] | Phase 3 | 29 participants (Actual) | Interventional | 2014-08-01 | Completed | ||
| Intravenous Lidocaine for Preventing Painful Oxaliplatin-induced Peripheral Neuropathy (OIPN)[NCT03254394] | Phase 1/Phase 2 | 26 participants (Actual) | Interventional | 2017-09-15 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The cumulative dose of oxaliplatin received over the course (up to 12 cycles) of mFOLFOX6 treatment regimen. It corresponds to the absolute summed up quantity of Oxaliplatin administered to the patient over time. There is no range for this measure. Since this is a dose-limiting neuropathy prevention study, the higher value can be interpreted as better outcome. (NCT03254394)
Timeframe: 24 weeks
| Intervention | mg (Mean) |
|---|---|
| Placebo + FOLFOX | 1161.8 |
| Lidocaine + FOLFOX | 1294.8 |
"The intensity of cold pain and cold unpleasantness is evaluated separately, assessed daily on a 0-10 scale, upon holding a pre-cooled (~8°C) metal cylinder for 10 seconds. the area under the curve of cold pain and cold unpleasantness vs time is calculated per chemotherapy cycle (every two weeks) and serves as a primary outcome measure.~For intervention (lidocaine+FOLFOX) and control (placebo+FOLFOX) groups, the average of cold pain AUC and cold unpleasantness AUC over 7 cycles was calculated. The average AUCs over 7 cycles were compared between study arms.~The AUC is measured as a score on a 0-10 scale multiplied by 14 days and may range between 0 and 140. Higher AUC values represent more intense cold pain/unpleasantness." (NCT03254394)
Timeframe: 14 weeks
| Intervention | score on a scale*days (Mean) | |
|---|---|---|
| pain AUC | unpleasantness AUC | |
| Lidocaine + FOLFOX | 9.5 | 25.4 |
| Placebo + FOLFOX | 16.4 | 33.1 |
Changes in Neuropathic Pain Symptom Inventory (NPSI) descriptors of neuropathic pain over time from baseline to cycle 3(6 weeks), cycle 6 (12 weeks), and the last follow-up (34-36 weeks). The total NPSI score ranges from 0 to 100; a higher NPSI total score represents a worse neuropathy outcome. The changes in scores from baseline are compared between study arms. (NCT03254394)
Timeframe: 6 weeks, 12 weeks, 34-36 weeks
| Intervention | score on a scale (Median) | ||
|---|---|---|---|
| 6 weeks visit | 12 weeks visit | last follow-up visit | |
| Lidocaine + FOLFOX | 0 | 0 | 13.5 |
| Placebo + FOLFOX | 0 | 0 | 3.0 |
"Change in CIPN (Chemotherapy-induced peripheral Neuropathy) score (on EORTC QLQ-CIPN20 tool ) from baseline to the Cycle 6 (12 weeks), and from baseline to last follow-up (34-36 weeks). EORTC QLQ-CIPN20 ranges from 0 (no symptoms) to 100 (worst symptoms). A higher score represents worse neuropathy. The changes in scores are compared between study arms.~EORTC QLQ-CIPN20 tool is a quality of life questionnaire (QLQ) from the European Organization for Research and Treatment of Cancer (EORTC) for evaluation of CIPN." (NCT03254394)
Timeframe: 12 weeks and 34-36 weeks
| Intervention | score on a scale (Median) | |
|---|---|---|
| 12 | 34-36 weeks | |
| Lidocaine + FOLFOX | 4 | 37.0 |
| Placebo + FOLFOX | 2 | 17.0 |
1 trial available for mexiletine and Allodynia
| Article | Year |
|---|---|
Systemic lidocaine in pain due to peripheral nerve injury and predictors of response.
Topics: Adult; Aged; Analgesics; Cold Temperature; Cross-Over Studies; Double-Blind Method; Female; Hot Temp | 2004 |
Systemic lidocaine in pain due to peripheral nerve injury and predictors of response.
Topics: Adult; Aged; Analgesics; Cold Temperature; Cross-Over Studies; Double-Blind Method; Female; Hot Temp | 2004 |
Systemic lidocaine in pain due to peripheral nerve injury and predictors of response.
Topics: Adult; Aged; Analgesics; Cold Temperature; Cross-Over Studies; Double-Blind Method; Female; Hot Temp | 2004 |
Systemic lidocaine in pain due to peripheral nerve injury and predictors of response.
Topics: Adult; Aged; Analgesics; Cold Temperature; Cross-Over Studies; Double-Blind Method; Female; Hot Temp | 2004 |
13 other studies available for mexiletine and Allodynia
| Article | Year |
|---|---|
Discovery of DS-1971a, a Potent, Selective Na
Topics: Analgesics; Animals; Drug Discovery; Female; Humans; Hyperalgesia; Macaca fascicularis; Male; Mice; | 2020 |
Behavioral and pharmacological characteristics of bortezomib-induced peripheral neuropathy in rats.
Topics: Administration, Ophthalmic; Analgesics; Animals; Antineoplastic Agents; Axons; Bortezomib; Duloxetin | 2015 |
Effects of Adjuvant Analgesics on Cerebral Ischemia-Induced Mechanical Allodynia.
Topics: Amines; Analgesics; Animals; Anti-Arrhythmia Agents; Anti-Inflammatory Agents, Non-Steroidal; Antico | 2016 |
Effect of mexiletine on dynamic allodynia induced by chronic constriction injury of the sciatic nerve in rats.
Topics: Analgesics; Animals; Chronic Disease; Constriction, Pathologic; Dose-Response Relationship, Drug; Hy | 2009 |
Etodolac, a cyclooxygenase-2 inhibitor, attenuates paclitaxel-induced peripheral neuropathy in a mouse model of mechanical allodynia.
Topics: Animals; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Disease Models, Animal; Drug Int | 2012 |
Effect of mexiletine on vincristine-induced painful neuropathy in mice.
Topics: Animals; Arginine; Behavior, Animal; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibi | 2006 |
Potent analgesic effects of a putative sodium channel blocker M58373 on formalin-induced and neuropathic pain in rats.
Topics: Analgesics; Animals; Cells, Cultured; Dose-Response Relationship, Drug; Formaldehyde; Ganglia, Spina | 2006 |
The effects of mexiletine, desipramine and fluoxetine in rat models involving central sensitization.
Topics: Animals; Anti-Arrhythmia Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tr | 1997 |
[Antinociceptive effects of the enantiomorphs and its main metabolite in streptozotocin-induced diabetic mice].
Topics: Animals; Anti-Arrhythmia Agents; beta-Endorphin; Diabetes Mellitus, Experimental; Diabetic Neuropath | 2000 |
Effect of mexiletine on thermal allodynia and hyperalgesia in diabetic mice.
Topics: Analgesics; Animals; Capsaicin; Diabetes Complications; Drug Interactions; Hot Temperature; Hyperalg | 2000 |
Lack of stereoselectivity for the antiallodynic effect of mexiletine in spinally injured rats.
Topics: Analgesics; Animals; Behavior, Animal; Disease Models, Animal; Drug Evaluation, Preclinical; Female; | 2000 |
Nociception and allodynia/hyperalgesia induced by intrathecal administration of fenvalerate.
Topics: Animals; Behavior, Animal; Dizocilpine Maleate; Enzyme Activators; Enzyme Inhibitors; Hyperalgesia; | 2001 |
Analgesic activity of a novel use-dependent sodium channel blocker, crobenetine, in mono-arthritic rats.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Benzomorphans | 2001 |